Payment overview · 2025
General Payments
$335.20
17 reported records · 10 companies
Healthcare provider profile · identity verified
Anil Kumar Kakumanu
Allopathic & Osteopathic Physicians|Internal Medicine · BATAVIA, OH · NPI 1922287515
Verified facts
What the public records show
CMS Open Payments records show Anil Kumar Kakumanu received $335.20 in general payments during 2025 across 17 reported records.
ABBVIE INC. accounted for 29.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $99.65 | 29.7% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $51.24 | 15.3% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.42 | 13.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $37.80 | 11.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.82 | 6.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.30 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.64 | 5.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.65 | 5.0% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.87 | 4.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.81 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $335.20 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $70.59 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $45.42 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.81 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $37.80 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $36.95 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $29.06 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.82 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.30 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $14.29 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 27 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 93 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 70 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
93 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
70 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 739 | 214 |
| Amlodipine Besylate | Amlodipine Besylate | 585 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 518 | 140 |
| Omeprazole | Omeprazole | 345 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 339 | 129 |
| Gabapentin | Gabapentin | 338 | 113 |
| Metoprolol Succinate | Metoprolol Succinate | 315 | 102 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 308 | 59 |
| Losartan Potassium | Losartan Potassium | 300 | 90 |
| Lisinopril | Lisinopril | 257 | 88 |
| Furosemide | Furosemide | 244 | 100 |
| Metformin Hcl | Metformin Hcl | 243 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 70 |
| Doxazosin Mesylate | Doxazosin Mesylate | 211 | 58 |
| Eliquis | Apixaban | 200 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 189 | 56 |
| Meloxicam | Meloxicam | 182 | 76 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 175 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 64 |
| Trazodone Hcl | Trazodone Hcl | 173 | 52 |
| Prednisone | Prednisone | 168 | 145 |
| Atenolol | Atenolol | 156 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 153 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 151 | 44 |
| Simvastatin | Simvastatin | 147 | 44 |
| Tramadol Hcl | Tramadol Hcl | 146 | 42 |
| Azithromycin | Azithromycin | 142 | 115 |
| Allopurinol | Allopurinol | 132 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 131 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 127 | 42 |
| Alprazolam | Alprazolam | 125 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 121 | 34 |
| Montelukast Sodium | Montelukast Sodium | 120 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 43 |
| Metformin Hcl Er | Metformin Hcl | 116 | 39 |
| Glimepiride | Glimepiride | 115 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 111 | 31 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 109 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 102 | 24 |
| Clonazepam | Clonazepam | 96 | 25 |
| Alendronate Sodium | Alendronate Sodium | 95 | 29 |
| Jardiance | Empagliflozin | 93 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 25 |
| Sertraline Hcl | Sertraline Hcl | 89 | 27 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 86 | 28 |
| Glipizide Er | Glipizide | 85 | 26 |
| Glipizide | Glipizide | 84 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 24 |
| Potassium Chloride | Potassium Chloride | 78 | 29 |
| Carvedilol | Carvedilol | 76 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 63 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 72 | 26 |
| Ozempic | Semaglutide | 70 | 13 |
| Buspirone Hcl | Buspirone Hcl | 67 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 19 |
| Pregabalin | Pregabalin | 66 | 17 |
| Fenofibrate | Fenofibrate | 64 | 13 |
| Lorazepam | Lorazepam | 62 | 23 |
| Donepezil Hcl | Donepezil Hcl | 58 | 20 |
| Synthroid | Levothyroxine Sodium | 58 | 16 |
| Januvia | Sitagliptin Phosphate | 57 | 12 |
| Levofloxacin | Levofloxacin | 57 | 55 |
| Torsemide | Torsemide | 57 | 26 |
| Spironolactone | Spironolactone | 56 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 52 | 12 |
| Famotidine | Famotidine | 51 | 15 |
| Chlorthalidone | Chlorthalidone | 50 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 50 | 25 |
| Cephalexin | Cephalexin | 49 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 46 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 47 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 45 | 18 |
| Xarelto | Rivaroxaban | 45 | suppressed |
| Amoxicillin | Amoxicillin | 44 | 38 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 44 | suppressed |
| Diazepam | Diazepam | 44 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Celecoxib | Celecoxib | 43 | 12 |
| Finasteride | Finasteride | 43 | 16 |
| Ondansetron Odt | Ondansetron | 42 | 14 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 41 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 38 | 12 |
| Terazosin Hcl | Terazosin Hcl | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 15 |
| Primidone | Primidone | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 11 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 22 |
| Meclizine Hcl | Meclizine Hcl | 30 | 17 |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 27 |
| Entresto | Sacubitril/Valsartan | 27 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 27 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 13 |
| Sucralfate | Sucralfate | 26 | 13 |
| Telmisartan | Telmisartan | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | 11 |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Fluconazole | Fluconazole | 18 | 12 |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Dexamethasone | Dexamethasone | 17 | 17 |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Nystatin | Nystatin | 16 | 13 |
| Propafenone Hcl | Propafenone Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Olanzapine | Olanzapine | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Chlordiazepoxide-Amitriptyline | Amitriptyline/Chlordiazepoxide | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $335.20 · 17 records | ABBVIE INC. | AIRSUPRA, ENTRESTO, GEMTESA, JARDIANCE, LEQVIO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, WATCHMAN Access System | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error